Mol Biol Rep. 2025 Aug 1;52(1):777. doi: 10.1007/s11033-025-10864-x.
ABSTRACT
BACKGROUND: Gabapentin is the pharmacologic treatment of choice for symptom relief in diabetic neuropathy. However, its effect on high glucose (HG)-induced neurotoxicity and genotoxicity under diabetic neuropathy conditions remains unclear. The aim of this study was to investigate the effects of gabapentin on cytogenotoxicity in HG-induced neuropathy in dorsal root ganglion (DRG) neurons.
METHODS: DRG neurons were isolated from neonatal Sprague-Dawley rats (n = 10). After treatment of these neurons with HG (45 mmol/L) and gabapentin (1,10, 100, and 1000 µM), cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2 H-tetrazolium bromide (MTT) assay. Furthermore, the effects on DNA damage in DRG neurons exposed to HG (45 mmol/L) and gabapentin (10 and 100 µM) were investigated by comet assay.
RESULTS: When HG + Gabapentin (1 µM), HG + Gabapentin (10 µM), HG + Gabapentin (100 µM), and HG + Gabapentin (1000 µM) groups were compared with the HG group, no statistically significant change in cell viability was determined (p > 0.05). HG + Gabapentin (10 µM) and HG + Gabapentin (100 µM) groups were not statistically significant in genotoxicity compared to HG group (p > 0.05).
CONCLUSIONS: Our results suggest that gabapentin does not modulate HG-induced cytogenotoxicity in HG-exposed DRG neurons. Our findings, which emphasize the safety of gabapentin in diabetic neuropathy, need more detailed studies.
CLINICAL TRIAL NUMBER: Not applicable.
PMID:40748554 | DOI:10.1007/s11033-025-10864-x
